About ViaCell
ViaCell is a company based in Cambridge (United States) founded in 1994 was acquired by PerkinElmer in October 2007. ViaCell has raised $63 million across 2 funding rounds from investors including DWS, PerkinElmer and Nomura. ViaCell operates in a competitive market with competitors including GenVault Corporation, iSpecimen, Indivumed, BioStorage Technologies and AminoChain, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$63 M (USD)
in 2 rounds
-
Latest Funding Round
$15 M (USD), Private Equity Round
Nov 05, 2001
-
Investors
DWS
& 3 more
-
Employee Count
Employee Count
-
Acquired by
PerkinElmer
(Oct 01, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ViaCell
ViaCell has successfully raised a total of $63M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $15 million completed in November 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Private Equity Round — $15.0M
-
First Round
First Round
(14 Nov 2000)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2001 | Amount | Private Equity Round - ViaCell | Valuation |
investors |
|
| Nov, 2000 | Amount | Private Equity Round - ViaCell | Valuation |
investors |
Investors in ViaCell
ViaCell has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include DWS, PerkinElmer and Nomura.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Asset management services are offered by DWS to clients.
|
Founded Year | Domain | Location | |
|
Diversified asset management services are offered globally by the firm.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ViaCell
Financial Statements - ViaCell
Viacell Comparisons
Competitors of ViaCell
ViaCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenVault Corporation, iSpecimen, Indivumed, BioStorage Technologies and AminoChain, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biosamples are stabilized, transported, stored, and retrieved by GenVault.
|
|
| domain | founded_year | HQ Location |
Provider of a biorepository of human clinical specimens
|
|
| domain | founded_year | HQ Location |
Biospecimens are collected, preserved, and analyzed for oncology services.
|
|
| domain | founded_year | HQ Location |
Provides bio repository services
|
|
| domain | founded_year | HQ Location |
A blockchain-based platform for tokenizing and incentivizing stem cell donations
|
Latest news on Viacell
Frequently Asked Questions about ViaCell
ViaCell was founded in 1994 and raised its 1st funding round 6 years after it was founded.
ViaCell is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
ViaCell is a funded company, having raised a total of $63M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $48M, raised on Nov 14, 2000.
ViaCell is focused on the collection and preservation of umbilical cord blood stem cells. Its product ViaCord allows expectant families to preserve their babys umbilical cord blood at the time of birth and claims that it can be used for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. It also conducts RD to investigate potential therapeutic uses of umbilical cord blood-derived stem cells and address other maternal health needs.
ViaCell's top competitors include iSpecimen, AminoChain and GenVault Corporation.
ViaCell has 4 investors. Key investors include DWS, PerkinElmer, Nomura, and The Stephens Group.